Elligo Health Research®, a healthcare-enabling research organization, is launching their fully realized System of Accelerated Research (SOAR) model for decentralized (DCTs) and hybrid trial models with fully remote monitoring capabilities.
Only Elligo has developed as a continuum of technologies and data science capabilities; Elligo's SOARtm model expands patient access to reach diverse patient populations that typically don't have access to clinical research as a care option. The solution drives efficiency by enabling direct data from source to submission and full remote site access, empowering patients, physicians, and sponsors to conduct more trials efficiently and faster in traditional and decentralized models.
"We are extremely excited to launch our tech-enabled solution created to keep the patient and the physician at the heart of its design, while providing sponsors transparency," said John Potthoff, Ph.D., CEO of Elligo. "Our goal has always been to provide all patients with access to research as a healthcare option, which is important now more than ever as we navigate the future of clinical research."
SOAR not only mitigates risk, but adheres to regulations and improves data quality while decreasing resource requirements and costs associated with clinical research. Paired with technology-enabled services and expert personnel, this model accelerates research without compromising quality and integrity. This provides a pathway to either use traditional research sites, DCTs, or hybrid trials, seamlessly moving between options without causing disruption for any stakeholders. This modernizes clinical research for a new paradigm in a new age of clinical research.
About Elligo Health Research®
Elligo Health Research, a healthcare-enabling research organization, uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. Powered by our Goes Direct® approach and novel IntElligo® Research Stack clinical technology, our team provides access to the best healthcare experts, patients, and research technologies. We engage physicians and patients who otherwise would not participate in clinical research and accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. Learn more at elligodirect.com.
These press releases may also interest you